To include your compound in the COVID-19 Resource Center, submit it here.

Genentech’s Tecentriq meets PFS endpoint in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Tecentriq atezolizumab met the co-primary endpoint of improving progression-free survival in the Phase III IMpower150 trial as first-line treatment of advanced stage IV

Read the full 326 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers